SCHEMBL1925429

SCHEMBL1925429

NC(=O)c1[nH]cc(CCC(=O)O)c1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.46
TEK Q02763 2/20 0.44
FLT1 P17948 1/20 0.44
CHRNA7 P36544 1/20 0.44
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.42
KDR P35968 3/20 0.42
NTRK1 P04629 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
ALDH1A1 P00352 5/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925178 0.90 KDR (0.49) RIPK1TEKFLT1KDRNTRK1
SCHEMBL1925334 0.89 EPHX2 (0.48) MAPTMEN1KMT2AKDRCA12
SCHEMBL1924893 0.87 KDR (0.51) RIPK1KDRCA1CA2CA9
SCHEMBL1923967 0.86 MEN1 (0.51) RIPK1FLT1MAPTMEN1KMT2A
SCHEMBL1925039 0.85 RIPK1 (0.44) RIPK1MAPTMEN1KMT2AKDR
SCHEMBL1925498 0.85 RIPK1 (0.49) RIPK1TEKFLT1CHRNA7MAPT
SCHEMBL1924459 0.82 KDM4E (0.46) FLT1MAPTGAAMEN1KMT2A
SCHEMBL1924020 0.80 CDK8 (0.43) RIPK1FLT1KDRNTRK1
SCHEMBL1924464 0.80 ALDH1A1 (0.38) TEKMAPTMEN1KMT2AKDR
SCHEMBL1925914 0.80 CA12 (0.49) RIPK1FLT1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856043-B1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2011-06-08 EP claimed